The Pender Corporate Bond Fund enjoyed a profitable July, returning 1.5%[1]. The good result was due to a number of holding-specific catalyst events that allowed the Fund to outperform benchmarks. One key contributor for the period was our stake in the capital structure of Esperion Therapeutics Inc. Management’s successful efforts in extending the cholesterol-lowering drug […]

